The presentations during the FDA-AACR Liquid Biopsies in Oncology Drug and Device Development Workshop on July 19, 2016 included several important pieces of information that will likely guide the development of assays and their review by the FDA.
FDA-AACR Liquid Biopsies in Oncology Drug and Device Workshop
Important information for assay development and review by the FDA
0 Comments Click here to read/write comments
Topics: Diagnostics, LDT, Cancer Test, Circulating Tumor DNA, Clinical Testing, NGS, Precision Medicine, Mutation, ctDNA, FDA, Test Development, Reference Material, Oncology
Circulating tumor DNA liquid biopsy needs reference standards
How can you measure something without a ruler?
The science of metrology is tightly coupled with biological science, in tandem with biology becoming less descriptive and more quantitative over the past half-century. The US National Institute of Standards and Technology (NIST), an agency of the US Department of Commerce, has been established to ‘promote U.S. innovation and industrial competitiveness by advancing measurement science, standards and technology in ways that enhance economic security and improve our quality of life’.
0 Comments Click here to read/write comments
Topics: Diagnostics, #AMP2015, Circulating Tumor DNA, ctDNA, Test Development, Reference Material, Standard, Amp
In 2011, the National Academy of Science published the results of a year-long committee effort called ‘Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease’. This committee was charged to explore the feasibility and need to develop a new taxonomy of human disease based upon molecular biology, with the concept that with an explosion of molecular data about individuals with disease, there was a great untapped opportunity to use these data to improve health.
FLICKR, JOHN GOODE
0 Comments Click here to read/write comments
Topics: Diagnostics, Precision Medicine, Reference Material, SeraSeq
